Literature DB >> 20138542

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Karen E Knudsen1, Trevor M Penning.   

Abstract

Prostate cancer remains a leading cause of cancer death, as there are no durable means to treat advanced disease. Treatment of non-organ-confined prostate cancer hinges on its androgen dependence. First-line therapeutic strategies suppress androgen receptor (AR) activity, via androgen ablation and direct AR antagonists, whereas initially effective, incurable, 'castration-resistant' tumors arise as a result of resurgent AR activity. Alterations of AR and/or associated regulatory networks are known to restore receptor activity and support resultant therapy-resistant tumor progression. However, recent evidence also reveals an unexpected contribution of the AR ligand, indicating that alterations in pathways controlling androgen synthesis support castration-resistant AR activity. In this report, the mechanisms underlying the lethal pairing of AR deregulation and aberrant androgen synthesis in prostate cancer progression will be discussed. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20138542      PMCID： PMC2862880          DOI： 10.1016/j.tem.2010.01.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  94 in total

1.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

2.  Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Authors:  R S D Brown; J Edwards; A Dogan; H Payne; S J Harland; J M S Bartlett; J R W Masters
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

3.  Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.

Authors:  Charles J Ryan; Alex Smith; Priti Lal; Jaya Satagopan; Victor Reuter; Peter Scardino; William Gerald; Howard I Scher
Journal:  Urology       Date:  2006-10       Impact factor: 2.649

4.  Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.

Authors:  Carlos G Leon; Jennifer A Locke; Hans H Adomat; Susan L Etinger; Alexis L Twiddy; Rachel D Neumann; Colleen C Nelson; Emma S Guns; Kishor M Wasan
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

7.  Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer.

Authors:  Liliana A Ponguta; Christopher W Gregory; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

10.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer.

Authors:  O Harris Ford; Christopher W Gregory; Desok Kim; Andrew B Smitherman; James L Mohler
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450
View more
  137 in total

Review 1.  FOXA1: master of steroid receptor function in cancer.

Authors:  Michael A Augello; Theresa E Hickey; Karen E Knudsen
Journal:  EMBO J       Date:  2011-09-20       Impact factor: 11.598

2.  Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Jeffrey D Winkler; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2011-01-07       Impact factor: 2.823

3.  Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Mo Chen; Jeffrey D Winkler; Trevor M Penning
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 4.  [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors:  P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

5.  Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

Authors:  Mo Chen; Adegoke O Adeniji; Barry M Twenter; Jeffrey D Winkler; David W Christianson; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2012-03-29       Impact factor: 2.823

Review 6.  Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

Authors:  Melanie J Grubisha; Donald B DeFranco
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

7.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

8.  A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.

Authors:  Phumvadee Wangtrakuldee; Adegoke O Adeniji; Tianzhu Zang; Ling Duan; Buddha Khatri; Barry M Twenter; Michelle A Estrada; Tyler F Higgins; Jeffrey D Winkler; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-11       Impact factor: 4.292

9.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.

Authors:  Chen-Lin Hsieh; Teng Fei; Yiwen Chen; Tiantian Li; Yanfei Gao; Xiaodong Wang; Tong Sun; Christopher J Sweeney; Gwo-Shu Mary Lee; Shaoyong Chen; Steven P Balk; Xiaole Shirley Liu; Myles Brown; Philip W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 10.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.